DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism Journal Article


Authors: Jee, J.; Brannon, A. R.; Singh, R.; Derkach, A.; Fong, C.; Lee, A.; Gray, L.; Pichotta, K.; Luthra, A.; Diosdado, M.; Haque, M.; Guo, J.; Hernandez, J.; Garg, K.; Wilhelm, C.; Arcila, M. E.; Pavlakis, N.; Clarke, S.; Shah, S. P.; Razavi, P.; Reis-Filho, J. S.; Ladanyi, M.; Schultz, N.; Zwicker, J.; Berger, M. F.; Li, B. T.; Mantha, S.
Article Title: DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Abstract: Cancer-associated venous thromboembolism (VTE) is a major source of oncologic cost, morbidity and mortality. Identifying high-risk patients for prophylactic anticoagulation is challenging and adds to clinician burden. Circulating tumor DNA (ctDNA) sequencing assays (‘liquid biopsies’) are widely implemented, but their utility for VTE prognostication is unknown. Here we analyzed three plasma sequencing cohorts: a pan-cancer discovery cohort of 4,141 patients with non-small cell lung cancer (NSCLC) or breast, pancreatic and other cancers; a prospective validation cohort consisting of 1,426 patients with the same cancer types; and an international generalizability cohort of 463 patients with advanced NSCLC. ctDNA detection was associated with VTE independent of clinical and radiographic features. A machine learning model trained on liquid biopsy data outperformed previous risk scores (discovery, validation and generalizability c-indices 0.74, 0.73 and 0.67, respectively, versus 0.57, 0.61 and 0.54 for the Khorana score). In real-world data, anticoagulation was associated with lower VTE rates if ctDNA was detected (n = 2,522, adjusted hazard ratio (HR) = 0.50, 95% confidence interval (CI): 0.30–0.81); ctDNA− patients (n = 1,619) did not benefit from anticoagulation (adjusted HR = 0.89, 95% CI: 0.40–2.0). These results provide preliminary evidence that liquid biopsies may improve VTE risk stratification in addition to clinical parameters. Interventional, randomized prospective studies are needed to confirm the clinical utility of liquid biopsies for guiding anticoagulation in patients with cancer. © The Author(s) 2024.
Keywords: adolescent; adult; child; controlled study; aged; middle aged; major clinical study; genetics; prospective study; prospective studies; neoplasm; neoplasms; disease association; carcinoma, non-small-cell lung; cohort analysis; pathology; prediction; high risk patient; confidence interval; blood; anticoagulants; anticoagulation; hazard ratio; venous thromboembolism; anticoagulant agent; non small cell lung cancer; etiology; complication; machine learning; dna sequencing; humans; prognosis; human; male; female; article; circulating tumor dna; liquid biopsy
Journal Title: Nature Medicine
Volume: 30
Issue: 9
ISSN: 1078-8956
Publisher: Nature Publishing Group  
Date Published: 2024-09-01
Start Page: 2499
End Page: 2507
Language: English
DOI: 10.1038/s41591-024-03195-0
PUBMED: 39147831
PROVIDER: scopus
PMCID: PMC11405286
DOI/URL:
Notes: Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Simon Mantha -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Marc Ladanyi
    1332 Ladanyi
  2. Michael Forman Berger
    768 Berger
  3. Maria Eugenia Arcila
    668 Arcila
  4. Nikolaus D Schultz
    490 Schultz
  5. Angela Rose Brannon
    99 Brannon
  6. Simon H Mantha
    71 Mantha
  7. Pedram Razavi
    182 Razavi
  8. Bob Tingkan Li
    279 Li
  9. Mohammad Haque Haque
    12 Haque
  10. Sohrab Prakash Shah
    88 Shah
  11. Christopher Joseph Fong
    43 Fong
  12. Clare Jon Wilhelm
    25 Wilhelm
  13. Anisha Luthra
    26 Luthra
  14. Andriy Derkach
    167 Derkach
  15. Justin Jee
    55 Jee
  16. Jeffrey Zwicker
    46 Zwicker
  17. Rohan Singh
    8 Singh